{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+alafenamide&page=3", "query": { "intervention": "Tenofovir alafenamide", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 171, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+alafenamide&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+alafenamide&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T01:53:11.639Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03797014", "title": "B/F/TAF Switch Study for HIV-HBV Coinfection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV-1-infection", "Hepatitis B" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-04-30", "completion_date": "2023-05-05", "has_results": true, "last_update_posted_date": "2023-11-03", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797014" }, { "nct_id": "NCT06613685", "title": "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "lepetegravir", "type": "DRUG" }, { "name": "lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "lepetegravir/lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-10-21", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06613685" }, { "nct_id": "NCT05064020", "title": "Bictegravir in the Elderly Living With HIV (BICEP)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "State University of New York at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2020-08-01", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-06-04", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064020" }, { "nct_id": "NCT02607956", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2015-11-11", "completion_date": "2021-07-05", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607956" }, { "nct_id": "NCT03780543", "title": "A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Assembly Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "71 Years", "sex": "ALL", "summary": "18 Years to 71 Years" }, "enrollment_count": 92, "start_date": "2018-12-20", "completion_date": "2021-04-26", "has_results": true, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 17, "location_summary": "Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03780543" }, { "nct_id": "NCT06766331", "title": "Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid Use Disorder", "HIV", "Hepatitis C Virus", "Gonorrhea", "Chlamydia", "Syphilis", "Sexually Transmitted Infection", "Integrated Care", "Medications for Opioid Use Disorder" ], "interventions": [ { "name": "Integrated care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2028-04-03", "completion_date": "2029-06-29", "has_results": false, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 1, "location_summary": "Northport, New York", "locations": [ { "city": "Northport", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06766331" }, { "nct_id": "NCT03547908", "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1/HBV Co-Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "Placebo to match DTG", "type": "DRUG" }, { "name": "Placebo to match F/TDF", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" }, { "name": "F/TDF", "type": "DRUG" }, { "name": "Placebo to match B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2018-05-30", "completion_date": "2024-03-07", "has_results": true, "last_update_posted_date": "2025-03-19", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 4, "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547908" }, { "nct_id": "NCT05457530", "title": "Doravirine and Weight Gain in Antiretroviral Naive", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Body Weight Changes", "Human Immunodeficiency Virus", "ART", "Obesity", "Minority Health", "BMD", "Metabolic Syndrome", "Fasting" ], "interventions": [ { "name": "DOR/3TC/TDF", "type": "DRUG" }, { "name": "DOR + FTC/TAF", "type": "COMBINATION_PRODUCT" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Prism Health North Texas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2022-08-01", "completion_date": "2023-05-03", "has_results": false, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457530" }, { "nct_id": "NCT05502341", "title": "Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Bictegravir", "type": "DRUG" }, { "name": "Lenacapavir", "type": "DRUG" }, { "name": "BIC/LEN FDC", "type": "DRUG" }, { "name": "Stable Baseline Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 689, "start_date": "2022-08-16", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 40, "location_summary": "Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05502341" }, { "nct_id": "NCT02707601", "title": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection", "HCV Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "F/R/TAF", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-04-01", "completion_date": "2017-09-29", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-02T01:53:11.639Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707601" } ] }